Drug repurposing against SARS-CoV-2: A review based on principal reports
Archivos Venezolanos de Farmacologia y Terapeutica
; 41(9):635-646, 2022.
Article
in English
| EMBASE | ID: covidwho-2239913
Keywords
alpha1b interferon; alpha2a interferon; alpha2b interferon; anakinra; azithromycin; bamlanivimab plus etesevimab; beta interferon; beta1b interferon; chloroquine; colchicine; dexamethasone; favipiravir; gamma interferon; hydroxychloroquine; interleukin 6 receptor; ivermectin; lambda interferon; lopinavir plus ritonavir; molnupiravir; nafamstat; nirmatrelvir plus ritonavir; nitazoxanide; nucleoside; peginterferon; proteinase inhibitor; remdesivir; ribavirin; sofosbuvir; sofosbuvir plus velpatasvir; sotrovimab; tocilizumab; umifenovir; antiretroviral therapy; antiviral activity; chill; computer assisted tomography; coronavirus disease 2019; cytotoxicity; depression; drug repositioning; EC50; erythema; fever; genotype; headache; hospital mortality; hospitalization; human; immune response; intensive care unit; JAK-STAT signaling; Medline; Middle East respiratory syndrome coronavirus; myalgia; oxygen therapy; phase 2 clinical trial (topic); randomized controlled trial (topic); review; SARS coronavirus; ScienceDirect; Severe acute respiratory syndrome coronavirus 2; skin necrosis; systematic review; virus load; virus replication; virus shedding
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Observational study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
Archivos Venezolanos de Farmacologia y Terapeutica
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS